Company Overview and News

 
Insurance industry shift from coal could mean higher power prices

2018-05-20 theage.com.au
A quiet revolution is happening in insurance, as many of the industry's big players pull their backing and investment from the coal power sector, potentially raising the price of electricity.

 
Insurance industry shift from coal could mean higher power prices

2018-05-20 smh.com.au
A quiet revolution is happening in insurance, as many of the industry's big players pull their backing and investment from the coal power sector, potentially raising the price of electricity.

 
Sumitomo Mitsui Financial Group, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-18 seekingalpha
The following slide deck was published by Sumitomo Mitsui Financial Group, Inc. in conjunction with their 2018 Q1 earnings call.

 
Nikkei rises as financials, tech shares rally

2018-05-17 reuters
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average rose on Thursday after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields while tech shares attracted buyers after the yen weakened.

 
Nikkei rises in line with Wall Street gains; financials rally

2018-05-17 reuters
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average followed U.S. stocks higher on Thursday morning after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields.

 
Sumitomo Mitsui Signals It May Curb Coal-Fired Power Financing - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
SMFG / Sumitomo Mitsui Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-14 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K

 
SMFG / Sumitomo Mitsui Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-14 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K

 
SMFG / Sumitomo Mitsui Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-14 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K

 
SMFG / Sumitomo Mitsui Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-14 sec.gov
FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <

 
SMFG / Sumitomo Mitsui Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-14 sec.gov
Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Total net profit at Japan’s three mega-bank groups likely to grow for first time in four years

2018-05-08 japantimes.co.jp
The total net profit for Japan’s three mega-bank groups are believed to have grown year on year for the first time in four years in the fiscal year that ended in March.

 
Nikkei ekes out small gains on big-cap stocks; Sony stumbles on profit warning

2018-05-01 reuters
TOKYO, May 1 (Reuters) - Japan’s Nikkei eked out modest gains in holiday-thinned trade on Tuesday supported by buying in index-heavy stocks such as Fast Retailing and Fanuc, though Sony tumbled after the company issued a profit warning.

 
Nikkei flat in subdued holiday trade; Sony stumbles on profit warning

2018-05-01 reuters
TOKYO, May 1 (Reuters) - Japanese stocks were choppy in holiday-thinned trade on Tuesday, while Sony tumbled after the company issued a profit warning.

3
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2018 Update

2018-04-27 seekingalpha
Amazon.com, Alibaba Group Holdings, Visa Inc., Apple Inc., and Taiwan Semiconductor Manufacturing are the largest five individual stock positions.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 86562M209